On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-MyersSquibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves BristolMyersSquibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Results that may be inaccessible to you are currently showing.